Apar Pataer, MD, PhD
Department of Thoracic and Cardiovascular Surgery, Division of Surgery
About Dr. Pataer
Dr. Pataer is a translational researcher who obtained his M.D. from Xinjiang Medical College, Urumqi, Xinjiang, China and his Ph.D. in Cell Biology; Cancer Biology & Pathology from Kyoto University, Kyoto, Japan. After completion of his postdoctoral fellowship in the Department of Thoracic & Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, he was appointed as an Instructor and began his faculty career. He was promoted to Assistant Professor in 2004 and Associate Professor in 2011.
Read More
Present Title & Affiliation
Primary Appointment
Professor, Department of Thoracic and Cardiovascular Surgery - Research, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Dr. Pataer's unique abilities to work with others facilitate his success in our multidisciplinary efforts. Currently his significant accomplishments include validation of the importance of pathologic response in neoadjuvant treated non-small cell lung cancer treated with neoadjuvant chemotherapy. His lab based research efforts include promising and novel investigations of the role of misfolded protein, PKR associated biomarkers and the development of novel PKR associated small molecules.
Education & Training
Degree-Granting Education
| 1996 | Kyoto University, Kyoto, JP, Cell Biology; Cancer Biology & Pathology, Ph.D |
| 1988 | Xinjiang Medical College, Urumqi, Xinjiang, CN, MD |
Postgraduate Training
| 1998-2001 | Post-Doctoral Fellowship, Thoracic & Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas |
Experience & Service
Academic Appointments
Associate Professor, Department of Thoracic and Cardiovascular Surgery - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011 - 2022
Assistant Professor, Department of Thoracic and Cardiovascular Surgery - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - 2011
Assistant Professor, Department of Genitourinary Medical Oncology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2008
Assistant Professor, Department of Thoracic and Cardiovascular Surgery - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2004 - 2007
Instructor, Department of Thoracic and Cardiovascular Surgery - Research, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2001 - 2004
Assistant Professor, Department of Pathology/Laboratory Medicine, Kyoto University, Kyoto, 1996 - 1998
Part-time Physician, Department of Pathology, Otsu Red Cross Hospital, Otsu, 1992 - 1997
Part-time Physician, Department of Pathology, Kyoto University Hospital, Kyoto, 1991 - 1998
Attending Physician, Xinjiang People's Hospital, Urumqi, Xinjiang, 1988 - 1990
Institutional Committee Activities
Member, Clinical Protocol Review Committee, 2018 - Present
Honors & Awards
| 1998 | Young Investigator Award, Kyoto University |
| 1994 | Best Graduate Student Award, Society of Japanese Science |
| 1990 | Outstanding Employee, Xinjiang Academy of Medical Science |
| 1989 | Best Resident of the Year, Xinjiang People's Hospital |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Zhou N, Leung CH, William WN Jr, Weissferdt A, Pataer A, Godoy MCB, Carter BW, Fossella FV, Tsao AS, Blumenschein GR, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Tran HT, Wu J, Solis Soto LM, Kadara H, Swisher SG, Vaporciyan AA, Gibbons DL, Lin HY, Lee JJ, Heymach JV, Negrao MV, Sepesi B, Cascone T. Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. J Immunother Cancer 12(10), 2024. e-Pub 2024. PMID: 39448200.
- Tan, X, Wang, S, Xiao, GY, Wu, C, Liu, X, Zhou, B, Jiang, Y, Duose, D, Xi, Y, Wang, J, Gupta, K, Pataer, A, Roth, JA, Kim, M, Chen, F, Creighton, CJ, Russell, W, Kurie, JM. Chromosomal 3q amplicon encodes essential regulators of secretory vesicles that drive secretory addiction in cancer. Journal of Clinical Investigation 134(12), 2024. e-Pub 2024. PMID: 38662435.
- Feldman H, Sepesi B, Leung CH, Lin H, Weissferdt A, Pataer A, William WN, Walsh GL, Rice DC, Roth JA, Reza Md J M, Hofstetter WL, Antonoff MB, Rajaram R, Gibbons DL, Lee JJ, Heymach JV, Vaporciyan AA, Swisher SG, Cascone T. Surgical Outcomes After Chemotherapy plus Nivolumab and Chemotherapy plus Nivolumab and Ipilimumab in Patients with Non-Small Cell Lung Cancer. J Thorac Cardiovasc Surg 167(4):1444-1453.e4, 2024. e-Pub 2023. PMID: 37816395.
- Weissferdt A, Leung CH, Lin H, Sepesi B, William WN, Swisher SG, Cascone T, Lee JJ, Pataer A. Pathologic processing of lung cancer resection specimens after neoadjuvant therapy. Mod Pathol:100353. e-Pub 2023. PMID: 37844869.
- Lv X, Lu X, Cao J, Luo Q, Ding Y, Peng F, Pataer A, Lu D, Han D, Malmberg E, Chan DW, Wang X, Savage SR, Mao S, Yu J, Peng F, Yan L, Meng H, Maneix L, Han Y, Chen Y, Yao W, Chang EC, Catic A, Lin X, Miles G, Huang P, Sun Z, Burt B, Wang H, Wang J, Yao QC, Zhang B, Roth JA, O'Malley BW, Ellis MJ, Rimawi MF, Ying H, Chen X. Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors. Science 381(6662):eabn4180, 2023. e-Pub 2023. PMID: 37676964.
- Cascone T, Leung CH, Weissferdt A, Pataer A, Carter BW, Godoy MCB, Feldman H, William WN, Xi Y, Basu S, Sun JJ, Yadav SS, Rojas Alvarez FR, Lee Y, Mishra AK, Chen L, Pradhan M, Guo H, Sinjab A, Zhou N, Negrao MV, Le X, Gay CM, Tsao AS, Byers LA, Altan M, Glisson BS, Fossella FV, Elamin YY, Blumenschein G, Zhang J, Skoulidis F, Wu J, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Rajaram R, Antonoff MB, Fujimoto J, Solis LM, Parra ER, Haymaker C, Wistuba II, Swisher SG, Vaporciyan AA, Lin HY, Wang J, Gibbons DL, Jack Lee J, Ajami NJ, Wargo JA, Allison JP, Sharma P, Kadara H, Heymach JV, Sepesi B. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med 29(3):593-604, 2023. e-Pub 2023. PMID: 36928818.
- Sepesi B, Zhou N, William WN, Lin HY, Leung CH, Weissferdt A, Mitchell KG, Pataer A, Walsh GL, Rice DC, Roth JA, Mehran RJ, Hofstetter WL, Antonoff MB, Rajaram R, Negrao MV, Tsao AS, Gibbons DL, Lee JJ, Heymach JV, Vaporciyan AA, Swisher SG, Cascone T. Surgical outcomes after nivolumab or nivolumab with ipilimumab treatment in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg 164(5):1327-1337, 2022. e-Pub 2022. PMID: 35190177.
- Pataer A, Weissferdt A, Correa AM, Vaporciyan AA, Sepesi B, Heymach JV, Berezowska S, Cascone T, Swisher SG. Major Pathologic Response and Prognostic Score Predict Survival in Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy. JTO Clin Res Rep 3(11):100420, 2022. e-Pub 2022. PMID: 36389133.
- Rocha P, Zhang J, Laza-Briviesca R, Cruz-Bermúdez A, Bota-Rabassedas N, Sanchez-Espiridion B, Yoshimura K, Behrens C, Lu W, Tang X, Pataer A, Parra ER, HaymakerC, Fujimoto J, Swisher SG, Heymach JV, Gibbons DL, Lee JJ, Sepesi B, Cascone T, Solis LM, Provencio M, Wistuba II, Kadara H. Distinct immune gene programs associated with host tumor immunity, neoadjuvant chemotherapy and chemoimmunotherapy in resectable NSCLC. Clin Cancer Res 28(11):2461-2473, 2022. e-Pub 2022. PMID: 35394499.
- Zhang X, Zhang R, Ren C, Xu Y, Wu S, Meng C, Pataer A, Song X, Zhang J, Yao Y, He H, Chen H, Ma W, Wang J, Meric-Bernstam F, Champlin RE, Heymach JV, Rooney CM, Swisher SG, Vaporciyan AA, Roth JA, You MJ, Wang ML, Fang B. Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo. Blood Adv 6(3):891-901, 2022. e-Pub 2021. PMID: 34861697.
- Pataer A, Weissferdt A, Vaporciyan AA, Correa AM, Sepesi B, Wistuba II, Heymach JV, Cascone T, Swisher SG. Evaluation of Pathologic Response in Lymph Nodes of Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy. J Thorac Oncol 16(8):1289-1297, 2021. e-Pub 2021. PMID: 33857666.
- Cascone T, Weissferdt A, Godoy MCB, William WN, Leung CH, Lin HY, Basu S, Yadav SS, Pataer A, Mitchell KG, Khan MAW, Shi Y, Haymaker C, Solis LM, Parra ER, Kadara H, Wistuba II, Sharma P, Allison JP, Ajami NJ, Wargo JA, Jenq RR, Gibbons DL, Lee JJ, Swisher SG, Vaporciyan AA, Heymach JV, Sepesi B. Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. Nat Commun 12(1):5045, 2021. e-Pub 2021. PMID: 34413300.
- Weissferdt A, Pataer A, Swisher SG, Heymach JV, Gibbons DL, Cascone T, Sepesi B. Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment. Lung Cancer 154:76-83, 2021. e-Pub 2021. PMID: 33631448.
- Cascone T, William WN, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med 27(3):504-514, 2021. e-Pub 2021. PMID: 33603241.
- Corsini EM, Weissferdt A, Pataer A, Zhou N, Antonoff MB, Hofstetter WL, Mehran RJ, Rajaram R, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Cascone T, Heymach JV, Swisher SG, Sepesi B. Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy. Eur J Cardiothorac Surg 59(1):100-108, 2021. e-Pub 2021. PMID: 32864702.
- Weissferdt A, Pataer A, Vaporciyan AA, Correa AM, Sepesi B, Moran CA, Wistuba II, Roth JA, Shewale JB, Heymach JV, Kalhor N, Cascone T, Hofstetter WL, Lee JJ, Swisher SG. Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy. Clin Lung Cancer 21(4):341-348, 2020. e-Pub 2020. PMID: 32279936.
- Zhang X, Zhang R, Chen H, Wang L, Ren C, Pataer A, Wu S, Meng QH, Ha MJ, Morris J, Xi Y, Wang J, Zhang J, Gibbons DL, Heymach JV, Meric-Bernstam F, Minna J, Swisher SG, Roth JA, Fang B. KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations. Am J Cancer Res 10(12):4464-4475, 2020. e-Pub 2020. PMID: 33415011.
- Chen Y, Zhang R, Wang L, Correa AM, Pataer A, Xu Y, Zhang X, Ren C, Wu S, Meng QH, Fujimoto J, Jensen VB, Antonoff MB, Hofstetter WL, Mehran RJ, Pisimisis G, Rice DC, Sepesi B, Vaporciyan AA, Walsh GL, Swisher SG, Roth JA, Heymach JV, Fang B. Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice. Cancer 125(21):3738-3748, 2019. e-Pub 2019. PMID: 31287557.
- Pataer A, Ozpolat B, Shao R, Cashman NR, Plotkin SS, Samuel CE, Lin SH, Kabil NN, Wang J, Majidi M, Fang B, Roth JA, Vaporciyan AA, Wistuba II, Hung MC, Swisher SG. Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells. Oncogene. e-Pub 2019. PMID: 31554935.
- Asik E, Akpinar Y, Caner A, Kahraman N, Guray T, Volkan M, Albarracin C, Pataer A, Arun B, Ozpolat B. EF2-kinase targeted cobalt-ferrite siRNA-nanotherapy suppresses BRCA1-mutated breast cancer. Nanomedicine (Lond) 14(17):2315-2338, 2019. e-Pub 2019. PMID: 31432749.
- Baity M, Wang L, Correa AM, Zhang X, Zhang R, Pataer A, Wu S, Meng QH, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Zhao M, Gu J, Fang B. Glutathione reductase (GSR) gene deletion and chromosome 8 aneuploidy in primary lung cancers detected by fluorescence in situ hybridization. Am J Cancer Res 9(6):1201-1211, 2019. e-Pub 2019. PMID: 31285952.
- Pu X, Zhang R, Wang L, Chen Y, Xu Y, Pataer A, Meraz IM, Zhang X, Wu S, Wu L, Su D, Mao W, Heymach JV, Roth JA, Swisher SG, Fang B. Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer. J Transl Med 16(1):328, 2018. e-Pub 2018. PMID: 30477533.
- Bircan HA, Gurbuz N, Pataer A, Caner A, Kahraman N, Bayraktar E, Bayraktar R, Erdogan MA, Kabil N, Ozpolat B. Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer. Lung Cancer 124:31-39, 2018. e-Pub 2018. PMID: 30268477.
- Pataer A, Shao R, Correa AM, Behrens C, Roth JA, Vaporciyan AA, Wistuba II, Swisher SG. Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy. Cancer Med 7(6):2405-2414, 2018. e-Pub 2018. PMID: 29673125.
- Parra ER, Villalobos P, Behrens C, Jiang M, Pataer A, Swisher SG, William WN, Zhang J, Lee J, Cascone T, Heymach JV, Forget MA, Haymaker C, Bernatchez C, Kalhor N, Weissferdt A, Moran C, Zhang J, Vaporciyan A, Gibbons DL, Sepesi B, Wistuba II. Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. J Immunother Cancer 6(1):48, 2018. e-Pub 2018. PMID: 29871672.
- Cascone T, Gold KA, Swisher SG, Liu DD, Fossella FV, Sepesi B, Pataer A, Weissferdt A, Kalhor N, Vaporciyan AA, Hofstetter WL, Wistuba II, Heymach JV, Kim ES, William WN. Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer. Ann Thorac Surg 105(2):418-424, 2018. e-Pub 2018. PMID: 29217088.
- Gentile E, Oba T, Lin J, Shao R, Meng F, Cao X, Lin HY, Mourad M, Pataer A, Baladandayuthapani V, Cai D, Roth JA, Ji L. Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics. Oncotarget 8(29):48222-48239, 2017. e-Pub 2017. PMID: 28637023.
- Dalvi MP, Wang L, Zhong R, Kollipara RK, Park H, Bayo J, Yenerall P, Zhou Y, Timmons BC, Rodriguez-Canales J, Behrens C, Mino B, Villalobos P, Parra ER, Suraokar M, Pataer A, Swisher SG, Kalhor N, Bhanu NV, Garcia BA, Heymach JV, Coombes K, Xie Y, Girard L, Gazdar AF, Kittler R, Wistuba II, Minna JD, Martinez ED. Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors. Cell Rep 19(8):1669-1684, 2017. e-Pub 2017. PMID: 28538184.
- Hao C, Shao R, Raju U, Fang B, Swisher SG, Pataer A. Accumulation of RNA-dependent protein kinase (PKR) in the nuclei of lung cancer cells mediates radiation resistance. Oncotarget 7(25):38235-38242, 2016. e-Pub 2016. PMID: 27203671.
- Bozorov K, Zhao JY, Elmuradov B, Pataer A, Aisa HA. Recent developments regarding the use of thieno[2,3-d]pyrimidin-4-one derivatives in medicinal chemistry, with a focus on their synthesis and anticancer properties. Eur J Med Chem 102:552-573, 2015. e-Pub 2015. PMID: 26312434.
- Guo C, Hao C, Shao R, Fang B, Correa AM, Hofstetter WL, Roth JA, Behrens C, Kalhor N, Wistuba II, Swisher SG, Pataer A. RNA-dependent protein kinase (PKR) depletes nutrients, inducing phosphorylation of AMP-activated kinase in lung cancer. Oncotarget 6(13):11114-24, 2015. e-Pub 2015. PMID: 25798539.
- Hao C, Wang L, Peng S, Cao M, Li H, Hu J, Huang X, Liu W, Zhang H, Wu S, Pataer A, Heymach JV, Eterovic AK, Zhang Q, Shaw KR, Chen K, Futreal A, Wang M, Hofstetter W, Mehran R, Rice D, Roth JA, Sepesi B, Swisher SG, Vaporciyan A, Walsh GL, Johnson FM, Fang B. Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. Cancer Lett 357(1):179-85, 2015. e-Pub 2015. PMID: 25444907.
- Hellmann MD, Chaft JE, William WN, Rusch V, Pisters KM, Kalhor N, Pataer A, Travis WD, Swisher SG, Kris MG, Collaborative Group UOTMALC. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol 15(1):e42-50, 2014. e-Pub 2014. PMID: 24384493.
- Guo C, Shao R, Correa AM, Behrens C, Johnson FM, Raso MG, Prudkin L, Solis LM, Nunez MI, Fang B, Roth JA, Wistuba II, Swisher SG, Lin T, Pataer A. Prognostic Significance of Combinations of RNA-Dependent Protein Kinase and EphA2 Biomarkers for NSCLC. J Thorac Oncol 8(3):301-308, 2013. e-Pub 2013. PMID: 23370317.
- William WN, Pataer A, Kalhor N, Correa AM, Rice DC, Wistuba II, Heymach J, Lee JJ, Kim ES, Munden R, Gold KA, Papadimitrakopoulou V, Swisher SG, Erasmus JJ, Research Group UOTMALCC. Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy. J Thorac Oncol 8(2):222-8, 2013. e-Pub 2013. PMID: 23287849.
- Guo C, Lu H, Gao W, Wang L, Lu K, Wu S, Pataer A, Huang M, El-Zein R, Lin T, Roth JA, Mehran R, Hofstetter W, Swisher SG, Wu X, Fang B. Insulin-like growth factor binding protein-2 level is increased in blood of lung cancer patients and associated with poor survival. PLoS One 8(9):e74973, 2013. e-Pub 2013. PMID: 24069370.
- Pataer A, Kalhor N, Correa AM, Raso MG, Erasmus JJ, Kim ES, Behrens C, Lee JJ, Roth JA, Stewart DJ, Vaporciyan AA, Wistuba II, Swisher SG, Research Group UOTMDALCC. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol 7(5):825-32, 2012. e-Pub 2012. PMID: 22481232.
- He Y, Zhou Z, Hofstetter WL, Zhou Y, Hu W, Guo C, Wang L, Guo W, Pataer A, Correa AM, Lu Y, Wang J, Diao L, Byers LA, Wistuba II, Roth JA, Swisher SG, Heymach JV, Fang B. Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters. PLoS One 7(2):e31087, 2012. e-Pub 2012. PMID: 22348039.
- He Y, Correa AM, Raso MG, Hofstetter WL, Fang B, Behrens C, Roth JA, Zhou Y, Yu L, Wistuba II, Swisher SG, Pataer A. The Role of PKR/eIF2a Signaling Pathway in Prognosis of Non-Small Cell Lung Cancer. PLoS One 6(11):e24855, 2011. e-Pub 2011. PMID: 22102852.
- Pataer A, Raso MG, Correa AM, Behrens C, Tsuta K, Solis L, Fang B, Roth JA, Wistuba II, Swisher SG. Prognostic significance of RNA-dependent protein kinase on non-small cell lung cancer patients. Clin Cancer Res 16(22):5522-8, 2010. e-Pub 2010. PMID: 20930042.
- Zhou Y, Hofstetter WL, He Y, Hu W, Pataer A, Wang L, Wang J, Zhou Y, Yu L, Fang B, Swisher SG. KLF4 inhibition of lung cancer cell invasion by suppression of SPARC expression. Cancer Biol Ther 9(7):507-13, 2010. e-Pub 2010. PMID: 20215880.
- Fuson KL, Zheng M, Craxton M, Pataer A, Ramesh R, Chada S, Sutton RB. Structural mapping of post-translational modifications in human interleukin-24: role of N-linked glycosylation and disulfide bonds in secretion and activity. J Biol Chem 284(44):30526-33, 2009. e-Pub 2009. PMID: 19734147.
- Hu W, Hofstetter WL, Li H, Zhou Y, He Y, Pataer A, Wang L, Xie K, Swisher SG, Fang B. Putative tumor-suppressive function of kruppel-like factor 4 in primary lung carcinoma. Clin Cancer Res 15(18):5688-95, 2009. e-Pub 2009. PMID: 19737957.
- Hu W, Hofstetter W, Wei X, Guo W, Zhou Y, Pataer A, Li H, Fang B, Swisher SG. Double-stranded RNA-dependent protein kinase-dependent apoptosis induction by a novel small compound. J Pharmacol Exp Ther 328(3):866-72, 2009. e-Pub 2009. PMID: 19066342.
- Pataer A, Swisher SG, Roth JA, Logothetis CJ, Corn PG. Inhibition of RNA-dependent protein kinase (PKR) leads to cancer cell death and increases chemosensitivity. Cancer Biol Ther 8(3):245-52, 2009. e-Pub 2009. PMID: 19106640.
- Hu W, Hofstetter W, Guo W, Li H, Pataer A, Peng HH, Guo ZS, Bartlett DL, Lin A, Swisher SG, Fang B. JNK-deficiency enhanced oncolytic vaccinia virus replication and blocked activation of double-stranded RNA-dependent protein kinase. Cancer Gene Ther 15(9):616-24, 2008. e-Pub 2008. PMID: 18535619.
- Pataer A, Hu W, Xiaolin L, Chada S, Roth JA, Hunt KK, Swisher SG. Adenoviral endoplasmic reticulum-targeted mda-7/interleukin-24 vector enhances human cancer cell killing. Mol Cancer Ther 7(8):2528-2535, 2008. e-Pub 2008. PMID: 18723497.
- Pataer A, Chada S, Roth JA, Hunt KK, Swisher SG. Development of Ad-mda7/IL-24-resistant lung cancer cell lines. Cancer Biol Ther 7(1):103-8, 2008. e-Pub 2008. PMID: 18059175.
- von Holzen U, Pataer A, Raju U, Bocangel D, Vorburger SA, Liu Y, Lu X, Roth JA, Aggarwal BB, Barber GN, Keyomarsi K, Hunt KK, Swisher SG. The double-stranded RNA-activated protein kinase mediates radiation resistance in mouse embryo fibroblasts through nuclear factor kappaB and Akt activation. Clin Cancer Res 13(20):6032-9, 2007. e-Pub 2007. PMID: 17947465.
- Takada Y, Ichikawa H, Pataer A, Swisher S, Aggarwal BB. Genetic deletion of PKR abrogates TNF-induced activation of Iκβα kinase, JNK, Akt and cell proliferation but potentiates p44/p42 MAPK and p38 MAPK activation. Oncogene 26(8):1201-1212, 2007. e-Pub 2007. PMID: 16924232.
- Pataer A, Bocangel D, Chada S, Roth JA, Hunt KK, Swisher SG. Enhancement of adenoviral MDA-7-mediated cell killing in human lung cancer cells by geldanamycin and its 17-allyl- amino-17-demethoxy analogue. Cancer Gene Ther 14(1):12-18, 2007. e-Pub 2007. PMID: 17024233.
- Pataer A, Fanale MA, Roth JA, Swisher SG, Hunt KK. Induction of apoptosis in human lung cancer cells following treatment with amifostine and an adenoviral vector containing wild-type p53. Cancer Gene Ther 13(8):806-814, 2006. e-Pub 2006. PMID: 16628227.
- Chada S, Mhashilkar AM, Liu Y, Nishikawa T, Bocangel D, Zheng M, Vorburger SA, Pataer A, Swisher SG, Ramesh R, Kawase K, Meyn RE, Hunt KK. mda-7 gene transfer sensitizes breast carcinoma cells to chemotherapy, biologic therapies and radiotherapy: correlation with expression of bcl-2 family members. Cancer Gene Ther 13(5):490-502, 2006. e-Pub 2006. PMID: 16282987.
- von Holzen U, Bocangel D, Pataer A, Vorburger SA, Liu Y, Lu X, Hunt KK, Swisher SG. Role for the double-stranded RNA-activated protein kinase PKR in Ad-TNF-alpha gene therapy in esophageal cancer. Surgery 138(2):261-268, 2005. e-Pub 2005. PMID: 16153435.
- Pataer A, Vorburger SA, Chada S, Balachandran S, Barber GN, Roth JA, Hunt KK, Swisher SG. Melanoma differentiation-associated gene-7 protein physically associates with the double-stranded RNA-activated protein kinase PKR. Mol Ther 11(5):717-723, 2005. e-Pub 2005. PMID: 15851010.
- Sieger KA, Mhashilkar AM, Stewart A, Sutton RB, Strube RW, Chen SY, Pataer A, Swisher SG, Grimm EA, Ramesh R, Chada S. The tumor suppressor activity of MDA-7/IL-24 is mediated by intracellular protein expression in NSCLC cells. Mol Ther 9(3):355-367, 2004. e-Pub 2004. PMID: 15006602.
- Vorburger SA, Pataer A, Swisher SG, Hunt KK. Genetically targeted cancer therapy: tumor destruction by PKR activation. Am J Pharmacogenomics 4(3):189-98, 2004. e-Pub 2004. PMID: 15174900.
- Pataer A, Chada S, Hunt KK, Roth JA, Swisher SG. Adenoviral melanoma differentiation-associated gene 7 induces apoptosis in lung cancer cells through mitochondrial permeability transition-independent cytochrome c release. J Thorac Cardiovasc Surg 125(6):1328-1335, 2003. e-Pub 2003. PMID: 12830052.
- Vorburger SA, Pataer A, Yoshida K, Liu Y, Lu X, Swisher SG, Hunt KK. The mitochondrial apoptosis-inducing factor plays a role in E2F-1-induced apoptosis in human colon cancer cells. Ann Surg Oncol 10(3):314-322, 2003. e-Pub 2003. PMID: 12679318.
- Vorburger SA, Pataer A, Yoshida K, Barber GN, Xia W, Chiao P, Ellis LM, Hung MC, Swisher SG, Hunt KK. Role for the double-stranded RNA activated protein kinase PKR in E2F-1-induced apoptosis. Oncogene 21(41):6278-6288, 2002. e-Pub 2002. PMID: 12214268.
- Nutt LK, Chandra J, Pataer A, Fang B, Roth JA, Swisher SG, O'Neil RG, McConkey DJ. Bax-mediated Ca2+ mobilization promotes cytochrome c release during apoptosis. J Biol Chem 277(23):20301-20308, 2002. e-Pub 2002. PMID: 11909872.
- Pataer A, Vorburger SA, Barber GN, Chada S, Mhashilkar AM, Zou-Yang H, Stewart AL, Balachandran S, Roth JA, Hunt KK, Swisher SG. Adenoviral transfer of the melanoma differentiation-associated gene 7 (mda7) induces apoptosis of lung cancer cells via up-regulation of the double-stranded RNA-dependent protein kinase (PKR). Cancer Res 62(8):2239-2243, 2002. e-Pub 2002. PMID: 11956076.
- Nutt LK, Pataer A, Pahler J, Fang B, Roth J, McConkey DJ, Swisher SG. Bax and Bak promote apoptosis by modulating endoplasmic reticular and mitochondrial Ca2+ stores. J Biol Chem 277(11):9219-9225, 2002. e-Pub 2002. PMID: 11741880.
- Pataer A, Smythe WR, Yu R, Fang B, McDonnell T, Roth JA, Swisher SG. Adenovirus-mediated Bak gene transfer induces apoptosis in mesothelioma cell lines. J Thorac Cardiovasc Surg 121(1):61-67, 2000. e-Pub 2000. PMID: 11135160.
- Pataer A, Fang B, Yu R, Kagawa S, Hunt KK, McDonnell TJ, Roth JA, Swisher SG. Adenoviral Bak overexpression mediates caspase-dependent tumor killing. Cancer Res 60(4):788-792, 2000. e-Pub 2000. PMID: 10706081.
- Hiai H, Pataer A, Nishimura M. Polygenic resistance to mouse pulmonary adenomas. Exp Lung Res 26:617-625, 2000. e-Pub 2000. PMID: 11195459.
- Pataer A, Mori TJ, Takahashi T, Tanaka F, Kasyu I, Sand H, Hiai, H. Loss of heterozygosity (LOH) at 17q and 14q in human lung cancers. Oncogene 17:3029-3033, 1998. e-Pub 1998. PMID: 9881705.
- Hiai H, Yamada Y, Shisa H, Kamoto T, Pataer A, Lu LM. To be or not to be a T-lymphomas, that is determined by a dominant gene Tlsm-1 in mouse models. Leukemia Suppl 3:193-194, 1998. e-Pub 1998.
- Lu LM, Ogawa M, Kamoto T, Yamada Y, Pataer A, Hiai H. Expression of LECAM-1 and LFA-1 on pre-B lymphoma cells but not on preneoplastic pre-B cells in SL/KH mice. Leuk Res 21(4):337-342, 1997. e-Pub 1997. PMID: 9150351.
- Pataer A, Nishimura M, Kamoto T, Ichioka K, Sato M, Hiai H. Genetic resistance to urethan-induced pulmonary adenomas in SMXA recombinant inbred mouse strains. Cancer Res 57(14):2904-2908, 1997. e-Pub 1997. PMID: 9230199.
- Hiai H, Pataer A, Nishimura M, Kamoto T. Pulmonary adenoma susceptibility and resistance genes. Mol Med 34:676-681, 1997. e-Pub 1997.
- Pataer A, Kamoto T, Lu LM, Yamada Y, Hiai H. Two dominant host resistance genes to pre-B lymphoma in wild-derived inbred mouse strain MSM/Ms. Cancer Res 56:3716-3720, 1996. e-Pub 1996. PMID: 8706013.
- Kamoto T, Shisa H, Pataer A, Lu L, Yoshida O, Yamada Y, Hiai H. A quantitative trait locus in major histocompatibility complex determining latent period of mouse lymphomas. Jpn J Cancer Res 87(4):401-404, 1996. e-Pub 1996. PMID: 8641972.
- Matsushima Y, Kamoto T, Ideda F, Pataer A, Hiai H. Rupture of lens cataract: a novel recessive mutant locus mapped on mouse chromosome. Genomics 20:125-127, 1996. e-Pub 1996.
- Pataer A, Yamada Y, Haller O, Kobayashi H, Kamoto T, Lu LM, Ogawa M, Ishimoto A, Katoh H, Kanehira K, Ikegami S, Fukumoto M, Hiai H. The origin of SL family mice. Lab Anim Sci 46(4):410-417, 1996. e-Pub 1996. PMID: 8872992.
- Pataer A, Matsushima Y, Komoto T, Lida F, Honda Y, Hiai H. Mapping of rupture of lens cataract (rlc) on mouse chromosome 14. Genomics 36:553-554, 1996. e-Pub 1996. PMID: 8884285.
- Hiai H Yamada Y, Shisa H, Ogawa M, Matsushiro H, Kamoto T, Pataer A. Host genetic determination of susceptibility and types of lymphomas. Radiat Biol Res 30:71-81, 1995. e-Pub 1995.
- Nakajima Y, Iwasa Y, Zhou J, Toyokuni S, Pataer A, Kakehi Y. Prostatic duct adenocarcinoma: (endometrioid carcinoma of the prostate). Hosp Pathol 12:128, 1995. e-Pub 1995.
- Sawada M, Horiguchi Y, Pataer A, Miyake N, Kitamura Y, Midorikawa O, Hiai H. Monoclonal antibodies to a zinc-binding protein of rat Paneth cells. J Histochem Cytochem 42:467-472, 1994. e-Pub 1994. PMID: 8126373.
Abstracts
- Deboever N, Leung CH, Lee Y, Mishra A, Federico L, Weissferdt A, Pataer A, Dejima H, Francisco-Cruz A, Alvarez FR, Solis LM, Parra ER, William Jr WN, Reuben A, Kadara H, Wistuba II, Zhang J, Swisher SG, Vaporciyan AA, Negrao MV, Bernatchez C, Wu J, Al-Lazikani B, Jaffray DA, Sepesi B, Ajami N, Wargo J, Futreal A, Heymach JV, Lin H, Lee J, Gibbons DL, Haymaker CL, Cascone T, Schmidt ST. Integrative machine learning for identifying treatment-specific impacts and biomarkers applied to multi-platform data from non-small-cell lung cancer treated with neoadjuvant chemoimmunotherapies. SITC 39th Annual Meeting & Pre-Conference Programs, 2024. e-Pub 2024.
- Weissferdt A, Leung H, Sepesi B, William WN, Lin H, Mehran RJ, Gibbons DL, Vaporciyan A, Heymach JV, Swisher SG, Lee JJ, Cascone T, Pataer A. Pathologic patterns following different neoadjuvant therapies in non-small cell lung cancer (NSCLC). ESMO Congress 2023, 2023. e-Pub 2023.
- Nelson DB, Pataer A, Correa AM, Weissferdt A, Antonoff MB, Cascone T, Hofstetter WL, Mehran RJ, Rajaram R, Rice DC, Walsh GL, Roth JA, Vaporciyan AA, Heymach JV, Sepesi B, Swisher SG. Relevance of Pathologic Downstaging After Neoadjuvant Chemotherapy for Lung Cancer. GTSC 35th Annual Meeting, 2023. e-Pub 2023.
- Rocha P, Zhang J, Laza-Briviesca R, Cruz-Bermúdez A, Bota-Rabassedas N, Sanchez-Espiridon B, Yoshimura K, Behrens C, Lu W, Tang X, Pataer A, Parra ER, Haymaker C, Fujimoto J, Swisher SG, Heymach JV, Gibbons DL, Lee JJ, Sepesi B, Cascone T, Solis LM, Provencio M, Kadara H, Wistuba II. Distinct immune gene programs associated with pre-existing host tumor immunity, neoadjuvant chemotherapy and chemoimmunotherapy in localized NSCLC. ESMO IO Congress, VIRTUAL, 2021. e-Pub 2021.
- Schmidt ST, Lee Y, Leung CH, Federico L, Solis LM, Parra ER, Lin H, Pradhan M, Guo H, Weissferdt A, Pataer A. Integrative immunomics highlight the immunomodulatory impact of neoadjuvant chemotherapy and immune-based treatments in resected non-small-cell lung cancer. SITC 36th Annual Meeting & Pre-Conference Programs, VIRTUAL, 2021. e-Pub 2021.
- Zhou N, Sepesi B, Leung CH, Lin HY, Jr WW, Weissferdt A, Pataer A, Godoy MCB, Fossella FV, Jr BG, Le X, Tsao AS, Zhang J, Hofstetter WL, Swisher SG, Vaporciyan AA, Lee JJ, Gibbons DL, Heymach JV, Cascone T. Impact of genomic aberrations and additional therapies on survival outcomes of patients with operable non-small cell lung cancer (NSCLC) from the NEOSTAR study. 2021 ASCO Annual Meeting, VIRTUAL, 2021. e-Pub 2021.
- Sepesi B, Corsini EM, Weissferdt A, Pataer A, Leung CH, Lin H, Le X, Mott F, Fossella F, Altan M, Tsao A, Skoulidis F, Blumenschein G, Kurie J, Zhang J, Glisson B, Lu C, Elamin Y, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Swisher SG, Vaporciyan AV, Walsh GL, Gibbons DL, Heymach JV, Cascone T. Combined Neoadjuvant Chemo-Immunotherapy Therapy Achieves Superior Downstaging of Resectable Non-Small Cell Lung Cancer as Compared to Chemotherapy, Mono Or Dual Immunotherapy. Society for Immunotherapy of Cancer Annual Meeting, 2020. e-Pub 2020.
- Corsini EM, Weissferdt A, Pataer A, Zhou N, Antonoff MB, Hofstetter WL, Mehran RJ, Rajaram R, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Cascone T, Heymach JV, Swisher SG, Sepesi B. Timing and patterns of recurrence in lung cancer patients with major pathologic response following neoadjuvant chemotherapy – the influence of persistent pathological nodal disease. ESTS 2020 Meeting, 2020. e-Pub 2020.
- Weissferdt A, Sepesi B, Pataer A, Kalhor N, Moran CA, William WN, Le X, Glisson B, Lu C, Skoulidis F, Blumenschein G, Zhang J, Altan M, Rice D, Mehran R, Vaporciyan A, Gibbons DL, Swisher SG, Heymach JV, Cascone T. Pathologic assessment following neoadjuvant immunotherapy or chemotherapy demonstrates similar patterns in non-small cell lung cancer (NSCLC). ESMO 2018, 2018. e-Pub 2018.
- Weissferdt A, Cascone T, Pataer A, Kalhor N, Moran C, Antonoff MB, Walsh GL, Bernatchez C, Gibbons DL, Wistuba II, Roth JA, Zhang J, Roarty E, Landry L, Vaporciyan AA, Heymach JV, Swisher S, Sepesi B. Histopathologic parameters define features of treatment response to neoadjuvant chemotherapy in non-small cell lung cancer. WCLC 2018, 2018. e-Pub 2018.
- Pataer A, Shao R, Correa AM, Wistuba II, Swisher SG. Major pathologic response (MPR) and biomarker predict survival in lung cancer patients receiving neoadjuvant chemotherapy. AACR 2018, 2018. e-Pub 2018.
- Pataer A, Shao R, Ozpolat B, Fang B, Swisher SG. PKR promotes EphA2 and other proteins degradation and is predictor of survival in lung cancer. AACR 2017, 2017. e-Pub 2017.
- Cuentas ER, Behrens C, Rodriguez-Canales J, Jiang M, Pataer A, Correa A, Swisher S, Sepesi B, Weissferdt A, Kalhor N, Zhang J, Lee J, Heymach J, Moran C, Zhang J, Gibbons D, Wistuba I. Neoadjuvant chemotherapy influence changes of the immune response in non-small cell lung carcinomas immune response in non-small cell lung carcinomas. AACR 2017, 2017. e-Pub 2017.
- Parra ER, Behrens C, Rodriguez-Canales J, Jian M, Pataer A, Correa A, Swisher SG, Sepesi B Weissferdt A, Kalhor N, William Jr WN, Lee J, Heymach JV, Moran C, Zhang J, Gibbons DL, Wistuba I. The Influence of Noeadjuvant Chemotherapy On Immune Profile In Non-Small Cell Lung Cancer. IASCL 17th World Conference on Lung Cancer 2016, 2016. e-Pub 2016.
- Pataer A, Chengcheng H, Correa AM, Fang B, Roth JA, Wistuba II, Swisher SG. PKR and Jagged1 associated with lymph node metastasis in lung cancer. Proc Am Assoc Cancer Res, New Orleans, Louisiana, 2016. e-Pub 2016.
- Pataer A, Wistuba II, Swisher SG. Biomarker associated with lymph node metastasis in lung cancer. Tenth AACR-JCA Joint Conference on Breakthroughs in Cancer Research: From Biology to Therapeutics, Maui, Hawaii, USA, 2016. e-Pub 2016.
- Pataer A, Ruping S, Correa AM, Carmen, Roth JA, Wistuba II, Swisher SG. Evaulate biomarkers in NSCLC tumors receiving neoadjuvant chemotherapy. Proc Am Assoc Cancer Res, 2015. e-Pub 2015.
- Pataer A, Guo C, Shao R, Correa AM, Behrens C, Fang B, Roth JA, Wistuba II, Swisher SG. Nutrient depletion caused by PKR induces phosphorylation of AMPK in lung cancer. American Association for Cancer Research, 2014. e-Pub 2014.
- Pataer A, Chengcheng G, Ruping S, Correa AM, Fang B, Roth JA, Wistuba II, Swisher SG. RNA-Dependent Protein Kinase (PKR) Depletes Nutrients, Inducing Phosphorylation of AMP-Activated Kinase in Lung Cancer. Proc Am Assoc Cancer Res, 2014. e-Pub 2014.
- Sepesi B, Correa AM, Pataer A, Kalhor N, Bekele NB, Erasmus JJ, Heymach J, Hofstetter WL, Komaki R, Mehran RJ, Moran CA, Gold K, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, William W, Wistuba I, Swisher SG. The Impact of Histopathologic Tumor Viability on AJCC 7th Lung Cancer Staging Following Neoadjuvant Chemotherapy. STS 2013, 2013. e-Pub 2013.
- Pataer A, Chengcheng G, Correa AM, Fang B, Roth JA, Wistuba II, Swisher SG. Prognostic Significance of Combinations of RNA-Dependent Protein Kinase and EphA2 Biomarkers for NSCLC. Proc Am Assoc Cancer Res, 2012. e-Pub 2012.
- He Y, Zhou Z, Hofstetter WL, Zhou Y, Hu W, Pataer A, Correa AM, Lu Y, Wang J, Diao L, Byers LA, Wistuba I, Roth JA, Swisher SG, Heymach JV, Fang B. Aberrant Signal Transduction and DNA Damage Response pathways in Primary Lung Cancer. ISLAC 2011 6(6, Supp 2):S972, 2011. e-Pub 2011.
- Pataer A, He Y, Correa AM, Fang B, Roth JA, Wistuba II, Swisher SG. PKR signaling pathway plays an important role in prognosis for non-small cell lung cancer. Proc Am Assoc Cancer Res, 2011. e-Pub 2011.
- Pataer A, Swisher SG, Roth JA, Logothetis CJ, Corn P. Inhibition of RNA-dependent protein kinase (PKR) leads to cancer cell death and increases chemosensitivity. Proc Am Assoc Cancer Res, 2010. e-Pub 2010.
- Pataer A, Roth JA, Swisher SG. Inhibition of RNA-dependent protein kinase (PKR) enhances radiation sensitivity in lung cancer cells. Proc Am Assoc Cancer Res, 2010. e-Pub 2010.
- Pataer A, Hu W, Lu X, Chada S, Roth J, Hunt K, Swisher S. Adenoviral ER-targeted mda-7/IL-24 vector enhances cell killing and overcomes MDA-7/IL-24 resistance. Proc Am Assoc Cancer Res, 2008. e-Pub 2008.
- Pataer A, Chada S, Roth JA, Hunt KK, Swisher SG. Development of Ad-mda7/IL-24-resistant lung cancer cells lines. Proc Am Assoc Cancer Res, 2008. e-Pub 2008.
- Pataer A, Chada S, Roth JA, Hunt KK, Swisher SG. Geldanamycin and its 17-allyl-amino-17-demethoxy analoue overcome Ad-mda-7 resistance in lung cancer cells. Proc Am Assoc Cancer Res, 2007. e-Pub 2007.
- Pataer A, Holzen UR, Bocangel D, Chada S, Roth JA, Hunt KK, Swisher SG. RNA-dependent protein kinase IPKR) indirectly regulates AKT in human lung cancer cells. Proc Am Assoc Cancer Res, 2006. e-Pub 2006.
- Bocangel DB, Holzen UV, Chada S, Pataer A, Takada Y, Raju U, Aggarwal BB, Barber GN, Chiao P, Milas L, Hunt KK, Swisher SG. Threshold for radiation sensitization induced by adenoviral delivery of TNF-alpha: Role of the double stranded RNA activated protein kinase (PKR). Proc Am Assoc Cancer Res, 2005. e-Pub 2005.
- Lu X, Pataer A, Hunt KK, Chada S, Swisher SG. ER targeting of Ad-MDA-7/IL-24 vectors increases apoptosis induction in esophageal and lung cancer cells. American Association for Cancer Research, 2005. e-Pub 2005.
- Pataer A, Bocangel D, Chada S, Roth JA, Hunt KK, Swisher SG. Enhancement of adenoviral mda-7 mediated cell killing in human lung cancer cells by geldanamycin and its 17-allylamino-17-demethoxy analogue overcome Ad-mda7 resistance in lung cancer cells. Proc Am Assoc Cancer Res, 2005. e-Pub 2005.
- von Holzen UW, Bocangel D, Pataer A, Takada Y, Liu Y, Aggarwal BB, Barber GN, Hunt KK, Swisher SG. Apoptosis of Esophageal Cancer Cells following Ad-TNFa gene therapy: the role of the double-stranded RNA activatedprotein kinase (PKR) and the nuclear factor kappa B (NF-kB). Proc Am Assoc Cancer Res 46, 2005. e-Pub 2005.
- von Holzen UW, Pataer A, Bocangel D, Lu X, Barber GN, Roth JA, Hunt KK, Swisher SG. Role for double-stranded RNA activated kinase PKR in Ad-TNFalpha gene therapy. Proc Soc Univ Surg, 2005. e-Pub 2005.
- von Holzen U, Pataer A, Bocangel D, Raju U, Vorburger SA, Liu Y, Lu X, Barber GN, Aggarwaal BB, Keyomarsi K, Hunt KK, Swisher SG. Lack of expression of the double-stranded RNA activated protein kinase PKR sensitizes mouse embryo fibroblasts to ionizing radiation. AACR-NCI-EORTC, 2005. e-Pub 2005.
- McKenzie T, Liu Y, Swisher S, Pataer A, Chada S, Fanale M, Hunt K. Combination therapy of Herceptin and Ad-mda7 inhibits growth of Her-2/neu overexpressing breast cancer in vivo. Proc Soc Surg Oncol, 2004. e-Pub 2004.
- Pataer A, Chada S, Hunt KK, Roth JA, Swisher SG. Adenoviral mda-7 induces apoptosis in p53 resistant lung cancer cells through PKR induction. Society of University Surgeons, 2004. e-Pub 2004.
- Pataer A, Vorburger S, Balachandran S, Barber GN, Chada S, Mhashilkar AM, Roth JA, Hunt KK, Swisher SG. Melanoma differentiation associated gene-7 protein physically associates with the double-stranded RNA activated protein kinase PKR. Proc Am Assoc Cancer Res 45:369, 2004. e-Pub 2004.
- Vorburger SA, Gu G, Fang B, Pataer A, Liu Y, Feig BW, Swisher SG, Hunt KK. Tumor-specific E2F-1 overexpression from the human telomerase reverse transcriptase (hTERT) promoter allows systemic treatment of colon cancer metastases. Proc Am Assoc Cancer Res 44:1298, 2003. e-Pub 2003.
- Pataer A, Chada S, Hunt KK, Roth JA, Swisher SG. Adenoviral MDA-7 induces apoptosis in lung cancer cells through mitochondrial permeability transition independent cytochrome C release. Proc Am Assoc Thor Surg 82:40, 2002. e-Pub 2002.
- Vorburger SA, Gu J, Fang B, Pataer A, Swisher SG, Hunt KK. Tumor-specific E2F-1 gene overexpression from the human telomerase reverse transcriptase (HTERT) promoter enables targeted apoptosis in colon cancer in-vivo. Proc Soc Univ Surg, 2002. e-Pub 2002.
- Vorburger SA, Pataer A, Barber GL, Liu Y, Swisher SG, Hunt KK. Adenoviral gene transfer of E2F-1 induces apoptosis through up-regulation of the dsRNA activated protein kinase PKR. . Proc Am Assoc Cancer Res 43:662, 2002. e-Pub 2002.
- Pataer A, Vorburger SA, Barber GL, Chada S, Balachandran S, Mhashilkar AM, Helena YH, Roth JA, Hunt, KK Swisher SG. MDA-7-induces apoptosis via regulation of the double stranded-RNA dependent protein kinase (PKR). Proc Am Assoc Cancer Res 43:1099, 2002. e-Pub 2002.
- Pataer A, Nutt L, Yu R, Mhashilkar A, Chada S, McConkey DJ, Hunt KK, Roth JA, Swisher SG. MDA-7 induces apoptosis by caspase activation through mitochondrial cytochrome c release. Proc Am Assoc Cancer Res 42:449, 2001. e-Pub 2001.
- Nutt LK, Pataer A, Pahler JC, McConkey D, Swisher SG. Expression of adenoviral bak and bax induces depletion of endoplasmic reticular calcium. Proc Am Assoc Cancer Res 42:306, 2001. e-Pub 2001.
- Swisher SG, Pataer A, Yu R, Nishizaki M, Fang B, Hunt KK, Roth JA. Enhancement of adenoviral mediated p53 (Adp53) tumor killing with amifostine induced cdc2 kinase activation 191:S88-S89, 2000. e-Pub 2000.
- Pataer A, Smythe WR, Yu R, Fang B, McDonnell T, Roth JA, Swisher SG. Adenovirus-mediated bak gene transfer induces apoptosis in mesothelioma cell lines. Proc Am Assoc Thorac Surg 41, 2000. e-Pub 2000.
- Pataer A, Fang B, Yu R, Kagawa S, Hunt KK, McDonnell T, Roth JA, Swisher SG. Adenoviral bak overexpression mediates caspase-dependent tumor killing. Proc Am Assoc Cancer Res 41:731, 2000. e-Pub 2000.
- Hiai H, Yamada Y, Pataer A, Lu L, Kamoto T, Tsuruyama T. Genetic and epigenetic susceptibility to endogenous retrovirus-induced lymphomas in SL mice. Prog Exp Tumor Res 35:64-77, 1999. e-Pub 1999.
- Pataer A, Mori TJ, Takahashi T, Tanaka F, Kasyu I, Hitomi S, Hiai H. Loss of heterozygosity (loh) at 17q and 14q in human lung cancers. Proc Jpn Pathol Assoc, 1998. e-Pub 1998.
- Pataer A, Yamada Y, Kamoto T, L-M L, Hiai H. Two dominant resistance genes to pre-B lymphomas in wild-derived inbred strains MSM/Ms. Second International Mouse Lung Tumorogenesis Symposium, 1997. e-Pub 1997.
- Pataer A, Nishimura M, Kamoto T, Hiai H. Genetic resistance to urethan-induced pulmonary adenomas in SMXA recombinant inbred mouse strains. Proc Jpn Cancer Assoc, 1997. e-Pub 1997.
- Pataer A, Mori TJ, Takahashi T, Tanaka F, Kasyu I, Hitomi S, Hiai H. Loss of heterozygosity (loh) at 17q and 14q in human lung cancers. Proc Jpn Cancer Assoc, 1997. e-Pub 1997.
- Pataer A, Yamada Y, Haller O, Kobayashi H, Kamoto T, Kanehira K, L-M L, Ishimoto A, Fukumoto M, Hiai H. The origin of SL family mice. Proc Jpn Pathol Asso, 1996. e-Pub 1996.
- Pataer A, Yamada Y, Kamoto T, L-M L, Hiai H. Two dominant resistance genes to pre-B lymphomas in wild-derived inbred strains MSM/Ms. Proc. Jpn. Cancer Assoc, 1996. e-Pub 1996.
- Pataer A, Matsushima Y, Kamoto T, Lida F, Honda Y, Hiai H. Mapping of rupture of lens cataract (rlc) on mouse chromosome 14. Pro Mol Genet Mouse, 1996. e-Pub 1996.
Book Chapters
- Chada S, Bocangel D, Pataer A, Sieger K, Mhashilkar AM, Inoue S, Miyahara R, Roth JA, Swisher S, Hunt KK, Ramesh R. MDA-7/IL-24 as a multi-modality therapy for cancer. In: Gene Therapy for Cancer. Humana Press, 413-434, 2007.
- Hiai H, Yamada Y, Pataer A, L-M L, Kamoto T, Tsuruyama T. Genetic and epigenetic susceptibility to endogenous retrovirus-induced lymphomas in SL mice. In: Animal models of cancer predisposition syndromes: Progress in Experimental Tumor Research. Karger, 64-77, 1999.
Selected Presentations & Talks
Formal Peers
- 2023. Translational Lung Cancer Research: From targeting pathway discovery to animal study to neoadjuvant trials. Invited. Houston, TX, US.
Grant & Contract Support
| Date: | 2025 - 2030 |
| Title: | Selectively targeting cancer survival pathway for lung cancer therapies |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R01CA306803-01/FP00024988 |
| Date: | 2025 - 2027 |
| Title: | Targeting PLD1 in Chromosome 3q-Amplified Non-Small Cell Lung |
| Funding Source: | Department of Defense (DOD) |
| Role: | Site PI |
| ID: | FP00023522/GRANT14222196 |
| Date: | 2024 - 2029 |
| Title: | Enhances efficacy of chemotherapy and immunotherapy by targeting multiple PKR mediated pathways in lung cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | FP00021598 |
| Date: | 2024 - 2028 |
| Title: | CRACD-controlled cell plasticity and small cell lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | R01CA278967-01A1 |
| Date: | 2023 - 2028 |
| Title: | Lysosome-targeted therapeutic strategy for lung cancer therapy |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | GRANT13783730 |
| Date: | 2023 - 2028 |
| Title: | PDXNet - Project 1: Developing therapeutic approaches to KRAS mutant and MAPK activated non-small cell lung cancer (NSCLC) based on vulnerabilities identified by molecular subtype using PDX derived organoids (PDOs) |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | U54CA224065 |
| Date: | 2023 - 2028 |
| Title: | PDXNet - Core D: Pilot Core |
| Funding Source: | NIH/NCI |
| Role: | Project Co-Leader |
| ID: | U54CA224065 |
| Date: | 2023 - 2028 |
| Title: | PDXNet - Core C: PDX Core |
| Funding Source: | NIH/NCI |
| Role: | Project Leader |
| ID: | U54CA224065 |
| Date: | 2023 - 2028 |
| Title: | CRACD controlled cell plasticity and small cell lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2023 - 2025 |
| Title: | An actionable secretory program that drives tumor progression in a genetically defined subset of lung squamous cell carcinoma |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | R03CA280382 |
| Date: | 2022 - 2027 |
| Title: | Bay Area & Anderson Team Against Acquired Resistance - U54 Program (BAATAAR-UP) |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | U54CA224081 |
| Date: | 2022 - 2027 |
| Title: | Targeting SMARCA2 as a therapeutic strategy in SMARCA4 mutant lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA272945 |
| Date: | 2022 - 2025 |
| Title: | Restoration of REQORSA(TUSC2) and NPRL2 expression to resensitize NSCLC and SCLC to targeted and immune therapies |
| Funding Source: | Genprex, Inc |
| Role: | Co-I |
| ID: | 00061014 |
| Date: | 2022 - 2023 |
| Title: | PDXNet: Pilot Project: Improving Match Trial Efficacy with Proteomic Study of PIK3CA Mutation |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | U54CA224065 |
| Date: | 2022 - 2023 |
| Title: | PDXNet: Pilot Project: PDXNet Image Analysis |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | U54CA224065 |
| Date: | 2021 - 2026 |
| Title: | Novel and highly specific therapeutic strategy for targeting the lysosomal pathway in cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | GRANT13270194 |
| Date: | 2021 - 2023 |
| Title: | Resectable, Early-stage (I [> 2 cm] to IIIA) Non-small Cell Lung Cancer (NeoCOAST) – Central Pathology Lab Protocol |
| Funding Source: | Medimmune |
| Role: | Co-I |
| ID: | PA19-0742 D9108C00002 |
| Date: | 2020 - 2025 |
| Title: | SPORE: Targeting Lung Cancer Vulnerabilities; Project 1: Targeting Metabolic Vulnerabilities in Lung Cancer |
| Funding Source: | NIH/NCI/UT Southwestern Medical Center |
| Role: | Co-I |
| ID: | P50CA070907 |
| Date: | 2020 - 2025 |
| Title: | Lysosome network regulates misfolded protein clearance and survival in lung cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Date: | 2020 - 2025 |
| Title: | Targeting SLC7A11-induced nutrient dependency in cancer: mechanisms and preclinical translation |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA244144 |
| Date: | 2020 - 2025 |
| Title: | Mechanisms and Vulnerabilities of SWI/SNF chromatin remodeling complex mutant lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R37CA251629 |
| Date: | 2020 - 2024 |
| Title: | Understand the function of PKR and target it for lung cancer therapy |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | GRANT12941937 |
| Date: | 2020 - 2025 |
| Title: | Discovery and therapeutic targeting of biological determinants of lung cancer health disparities |
| Funding Source: | NIH/NCI/University of Colorado |
| Role: | Co-I |
| ID: | R01CA239093 |
| Date: | 2020 - 2025 |
| Title: | PAF-Remodeled DREAM Complex in Cancer and Regeneration |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA193297 |
| Date: | 2019 - 2020 |
| Title: | PKR prevents misfolded PrP proteins release through multivesicular bodies (MVB)/exosomes |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| ID: | W81XWH-18-LCRP-IDA |
| Date: | 2019 - 2024 |
| Title: | Targeting PKR and EphA2 for personalized lung cancer therapy |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| Date: | 2019 - 2024 |
| Title: | Developing MPR and biomarker in NSCLC tumors receiving neoadjuvant chemotherapy |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | GRANT12629380 |
| Date: | 2019 - 2024 |
| Title: | Develop novel precision therapies for NSCLC with molecularly annotated PDX models |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | GRANT12629382 |
| Date: | 2018 - 2023 |
| Title: | PKR-guided personalized therapy for lung cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | GRANT12489047 |
| Date: | 2018 - 2022 |
| Title: | Impact of PKR on misfolded prion proteins and exosomes release in lung cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01CA225821 |
| Date: | 2017 - 2023 |
| Title: | PDXNet: Project 1: PDX-based trials of precision medicine for treatment of KRAS mutant lung cancers |
| Funding Source: | NIH/NCI |
| Role: | Project Lead |
| ID: | U54CA224065 |
| Date: | 2017 - 2023 |
| Title: | PDXNet: Core C: PDX Core |
| Funding Source: | NIH/NCI |
| Role: | Core Director |
| ID: | U54CA224065 |
| Date: | 2017 - 2022 |
| Title: | Enhancing Chemoradiation Efficacy through Unbiased Drug Discovery Approaches |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5U01CA216468-05 |
| Date: | 2017 - 2022 |
| Title: | Therapeutic targeting of lung cancers with aberrant glutathione homeostasis |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2017 - 2021 |
| Title: | Impact of PKR on prognosis in early stage lung cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Date: | 2016 - 2021 |
| Title: | Overcoming Platinum Resistance via Targeting the Proteasome in Cancer Cells |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2016 - 2019 |
| Title: | Prognostic biomarkers for early stage lung cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP170019 |
| Date: | 2016 - 2017 |
| Title: | Discovery biomarkers on non-small cell lung cancer |
| Funding Source: | UT MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2016 - 2017 |
| Title: | Identify biomarkers for non-small cell lung cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| Date: | 2015 - 2017 |
| Title: | Misfolding protein in lung cancer, Lung Cancer Research Program |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| Date: | 2013 - 2015 |
| Title: | Inhibiting the Notch Pathway Induces MET Confers Chemosensitivity in Lung Cancer |
| Funding Source: | The Hope Foundation |
| Role: | Co-PI |
| Date: | 2013 - 2015 |
| Title: | Developing response criteria and biomarker in NSCLC tumors receiving neoadjuvant chemotherapy |
| Funding Source: | MDACC |
| Role: | PI |
| Date: | 2012 - 2016 |
| Title: | Develop PKR and IGF-1 markers and elucidate their interaction for non-small cell lung cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Date: | 2011 - 2013 |
| Title: | Discovery and validation of biomarkers on non-small cell lung cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Date: | 2010 - 2012 |
| Title: | Identify biomarkers that contribute to the therapeutic resistance of lung cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Date: | 2010 - 2012 |
| Title: | Discovery and validation of biomarkers on non-small cell lung cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Date: | 2010 - 2012 |
| Title: | Identify PKR and IGF-1 Biomarkers for Non-Small Cell Lung Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Date: | 2009 - 2010 |
| Title: | Identify PKR and IGF-1 biomarkers for non-small cell lung cancer |
| Funding Source: | Lung Cancer Research Foundation |
| Role: | PI |
| Date: | 2007 - 2010 |
| Title: | PKR mediates a chemo-and-radio-resistance in cancer cells |
| Funding Source: | NIH/NHLBI |
| Role: | PI |
| ID: | R01 CA124388-01A1 |
| Date: | 2007 - 2010 |
| Title: | Enhancement of Ad-mda7 mediated killing by inhibiting AKT pathway |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Date: | 2003 - 2005 |
| Title: | MRP - Project 3 - Role of PKR in adenoviral TNF gene therapy strategies in esophageal cancer |
| Funding Source: | UTMDACC Multidisciplinary Research Program |
| Role: | Investigator |
| Date: | 2000 - 2001 |
| Title: | Novel gene therapeutics for the treatment of lung cancer identification & characterization of novel apoptotic genes by micro assay screening mthod |
| Funding Source: | NIH/NCI |
| Role: | Investigator |
| ID: | 1R43 CA86587-01 |
| Date: | 2000 |
| Title: | Gene therapeutics for the treatment of lung cancer identification and characterization of novel apoptotic genes by micro assay screening novel method |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R43 CA86587-1 |
| Title: | Targeting misfolded prion proteins and PKR for lung cancer therapy |
| Funding Source: | MDACC |
| Role: | PI |
| Title: | Identify biomarkers for chemosensitivity in lung cancer receiving neoadjuvant chemotherapy |
| Funding Source: | MDACC |
| Role: | PI |
| Title: | PKR/EphA2-guided personalized therapy for lung cancer |
| Funding Source: | MDACC |
| Role: | PI |
Patient Reviews
CV information above last modified June 24, 2025